Amit M. Oza

TL;DR: The 50-mg dosing regimen was better tolerated than the 200-mg arm, with gastrointestinal AEs being most common toxicities, and no associations were apparent between baseline tumor erbB expression profiles and PFS or OS.

TL;DR: It is indicated that multimodality postoperative treatment with paclitaxel and a platinum-based CT followed by APRT may increase the survival of patients with UPSC, but further prospective studies are needed to confirm these findings.

TL;DR: This review summarizes the current knowledge regarding the application of miRNAs as diagnostic, prognostic, and predictive biomarkers in ovarian cancer and highlights the potential of mi RNAs as a therapy in other cancers and how these therapies may be applied to ovarian cancer.

TL;DR: This phase I, open-label, dose-escalation study assesses the tolerability and toxicity profile of ≥ 2 doses of HGS-ETR1 administered IV in patients with advanced solid tumors or NHL and evaluates the pharmacokinetic (PK) profile and immunogenicity of H GS- ETR1.

TL;DR: The Gynecologic Cancer Intergroup (GCIG) 6th Ovarian Cancer Conference on Clinical Research was held virtually in October, 2021, following published consensus guidelines as discussed by the authors , and the goal of the consensus meeting was to achieve harmonisation on the design elements of upcoming trials in ovarian cancer, to select important questions for future study, and to identify unmet needs.